127 related articles for article (PubMed ID: 29049188)
1. Incidence of venous thromboembolism following the neoadjuvant chemotherapy regimen for epithelial type of ovarian cancer.
Chavan DM; Huang Z; Song K; Parimi LRH; Yang XS; Zhang X; Liu P; Jiang J; Zhang Y; Kong B; Li L
Medicine (Baltimore); 2017 Oct; 96(42):e7935. PubMed ID: 29049188
[TBL] [Abstract][Full Text] [Related]
2. Incidence of venous thromboembolism in patients with ovarian cancer receiving neoadjuvant chemotherapy: systematic review and meta-analysis.
Black KA; Bowden S; Chu P; McClurg C; Pin S; Metcalfe A
Int J Gynecol Cancer; 2024 Jun; 34(6):855-862. PubMed ID: 38431288
[TBL] [Abstract][Full Text] [Related]
3. Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome.
Brunekreeft KL; Paijens ST; Wouters MCA; Komdeur FL; Eggink FA; Lubbers JM; Workel HH; Van Der Slikke EC; Pröpper NEJ; Leffers N; Adam J; Pijper H; Plat A; Kol A; Nijman HW; De Bruyn M
Oncoimmunology; 2020 May; 9(1):1760705. PubMed ID: 32923120
[TBL] [Abstract][Full Text] [Related]
4. Tumour lysis syndrome in a patient with intravascular spread from a recurrent epithelial ovarian cancer.
Camarata M; Davies R; Copley S; Blagden S
BMJ Case Rep; 2013 Apr; 2013():. PubMed ID: 23616333
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.
Wakelee HA; Dahlberg SE; Keller SM; Tester WJ; Gandara DR; Graziano SL; Adjei AA; Leighl NB; Aisner SC; Rothman JM; Patel JD; Sborov MD; McDermott SR; Perez-Soler R; Traynor AM; Butts C; Evans T; Shafqat A; Chapman AE; Kasbari SS; Horn L; Ramalingam SS; Schiller JH;
Lancet Oncol; 2017 Dec; 18(12):1610-1623. PubMed ID: 29129443
[TBL] [Abstract][Full Text] [Related]
6. Systemic therapy for esophageal cancer: chemotherapy.
Ku GY
Chin Clin Oncol; 2017 Oct; 6(5):49. PubMed ID: 29129089
[TBL] [Abstract][Full Text] [Related]
7. Clinical validation of genetic variants associated with
Fasching PA; Häberle L; Rack B; Li L; Hein A; Ekici AB; Reis A; Lux MP; Cunningham JM; Ruebner M; Jenkins G; Fridley B; Schneeweiss A; Tesch H; Lichtenegger W; Fehm T; Heinrich G; Rezai M; Beckmann MW; Janni W; Weinshilboum RM; Wang L
Oncotarget; 2017 Sep; 8(44):78133-78143. PubMed ID: 29100455
[TBL] [Abstract][Full Text] [Related]
8. Everolimus Plus Letrozole for Treatment of Patients With HR
Safra T; Kaufman B; Kadouri L; Efrat Ben-Baruch N; Ryvo L; Nisenbaum B; Evron E; Yerushalmi R
Clin Breast Cancer; 2018 Apr; 18(2):e197-e203. PubMed ID: 29097108
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy.
Kim SH; Kim MJ; Kim YJ; Chang H; Kim JW; Lee JO; Lee KW; Kim JH; Bang SM; Lee JS
Medicine (Baltimore); 2017 Oct; 96(42):e8176. PubMed ID: 29049199
[TBL] [Abstract][Full Text] [Related]
10. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Colleoni M; Luo W; Karlsson P; Chirgwin J; Aebi S; Jerusalem G; Neven P; Hitre E; Graas MP; Simoncini E; Kamby C; Thompson A; Loibl S; Gavilá J; Kuroi K; Marth C; Müller B; O'Reilly S; Di Lauro V; Gombos A; Ruhstaller T; Burstein H; Ribi K; Bernhard J; Viale G; Maibach R; Rabaglio-Poretti M; Gelber RD; Coates AS; Di Leo A; Regan MM; Goldhirsch A;
Lancet Oncol; 2018 Jan; 19(1):127-138. PubMed ID: 29158011
[TBL] [Abstract][Full Text] [Related]
11. Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer.
Zhang J; Wang L; Wang Z; Wang B; Cao J; Lv F; Zhang S; Shao Z; Hu X
Oncotarget; 2017 Oct; 8(45):79527-79536. PubMed ID: 29108332
[TBL] [Abstract][Full Text] [Related]
12. Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.
Bubalo JS; Herrington JD; Takemoto M; Willman P; Edwards MS; Williams C; Fisher A; Palumbo A; Chen E; Blanke C; Lopez CD
Support Care Cancer; 2018 Apr; 26(4):1273-1279. PubMed ID: 29090385
[TBL] [Abstract][Full Text] [Related]
13. Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review.
Pellegrino B; Boggiani D; Tommasi C; Palli D; Musolino A
Acta Biomed; 2017 Oct; 88(3):329-333. PubMed ID: 29083340
[TBL] [Abstract][Full Text] [Related]
14. Niraparib in ovarian cancer: results to date and clinical potential.
Caruso D; Papa A; Tomao S; Vici P; Panici PB; Tomao F
Ther Adv Med Oncol; 2017 Sep; 9(9):579-588. PubMed ID: 29081841
[TBL] [Abstract][Full Text] [Related]
15.
Kanazawa Y; Yamada T; Fujita I; Kakinuma D; Matsuno K; Arai H; Shimoda T; Ko K; Kato S; Matsutani T; Hagiwara N; Nomura T; Uchida E
Anticancer Res; 2017 Nov; 37(11):6401-6405. PubMed ID: 29061825
[TBL] [Abstract][Full Text] [Related]
16. Mifepristone Has Limited Activity to Enhance the
Yang Y; Li X; Mamouni K; Kucuk O; Wu D
Anticancer Res; 2017 Nov; 37(11):6235-6243. PubMed ID: 29061806
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine, an Atypical Antipsychotic, Inhibits Survivin Expression and Sensitizes Cancer Cells to Chemotherapeutic Agents.
Sanomachi T; Suzuki S; Kuramoto K; Takeda H; Sakaki H; Togashi K; Seino S; Yoshioka T; Okada M; Kitanaka C
Anticancer Res; 2017 Nov; 37(11):6177-6188. PubMed ID: 29061799
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review and Meta-analysis of Retrospective Series of Regorafenib for Treatment of Metastatic Colorectal Cancer.
Mercier J; Voutsadakis IA
Anticancer Res; 2017 Nov; 37(11):5925-5934. PubMed ID: 29061771
[TBL] [Abstract][Full Text] [Related]
19. Nedaplatin-Induced Arrhythmia: Retrospective Analysis of Three Cases.
Song YJ; Fan T; Quan CY; Cao SH; Zhang Y; Shao XH
J Coll Physicians Surg Pak; 2017 Oct; 27(10):657-659. PubMed ID: 29056132
[TBL] [Abstract][Full Text] [Related]
20. Breast Cancer Survivorship Care Variations Between Adjuvant Chemotherapy Regimens.
Leal AD; Van Houten H; Sangaralingham L; Freedman RA; Jemal A; Neuman HB; Haddad TC; Mutter RW; Keegan THM; Mougalian SS; Loprinzi CL; Gross CP; Shah N; Ruddy KJ
Clin Breast Cancer; 2018 Aug; 18(4):e513-e520. PubMed ID: 29054689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
